Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the ...

Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind ...

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma.

Follicular lymphoma is considered an indolent disease, with long-term tumour control achieved by first-line ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and ...

IFLI has a proven track record of advancing lymphoma treatments through strategic funding and collaborative partnerships, including its support for groundbreaking research at Washington University in ...

At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition last month, the company announced positive ...